Latest News and Press Releases

RetinalGenix signs agreement to hire M. Cory Zwerling as its chief financial officer and interim chief operating officer, effective January 1, 2026

Annovis attends CTAD 2025 with two presentations highlighting new biomarker data in Alzheimer's and Parkinson's diseases.

MALVERN, Pa., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for...

MALVERN, Pa., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for...

Gnome Sciences Discovers Cancer Drug Shows Promise in Stopping Progression of ALS. BCL2 inhibitors such as venetoclax may treat neurodegenerative diseases

SAN FRANCISCO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- A comprehensive systematic review of lifestyle interventions to prevent cognitive decline, which published in the prestigious British medical journal...

All 84 sites for pivotal Phase 3 study in early AD are now fully activated, and the first group of patients has completed the 6-month treatment period.

SAN FRANCISCO, Oct. 21, 2025 (GLOBE NEWSWIRE) -- The NIH has awarded a new grant to Posit Science, the maker of the online BrainHQ brain exercises, to advance research, which showed in a...

The company aims to uncover molecular and cellular signatures associated with disease onset, progression, and risk, often before clinical symptoms appear.

RetinalGenix Technologies and RGEN Announce Strategic Collaboration to Advance Early Detection of Neurodegenerative, Systemic, and Retinal Diseases.